menu
    • menu
    [{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Bios Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Intravitreal Injection","sponsorNew":"ONL Therapeutics \/ Bios Partners","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Bios Partners"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"ONL Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AmbioPharm \/ ONL Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AmbioPharm \/ ONL Therapeutics"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Bios Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series C Financing","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"ONL Therapeutics \/ Bios Partners","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Bios Partners"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series D Financing","leadProduct":"ONL1204","moa":"","graph1":"Technology","graph2":"Approved","graph3":"ONL Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ONL Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"12","companyTruncated":"ONL Therapeutics \/ Johnson & Johnson"}]

    Find Clinical Drug Pipeline Developments & Deals for ONL1204

    Menu

    ONL1204

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Johnson & Johnson

                            Deal Size : $65.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing

                            Details : The funds will advance the development of ONL1204 Ophthalmic Solution by initiating a Phase 2 global study for treating GA associated with dry age-related macular degeneration.

                            Brand Name : ONL1204

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 13, 2024

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Johnson & Johnson

                            Deal Size : $65.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula...

                            Details : ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.

                            Brand Name : ONL1204

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 28, 2023

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Pa...

                            Details : ONL1204 is a novel, Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions. It is being investigated in patients with macula-off rhegmatogenous retinal ...

                            Brand Name : ONL1204

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 12, 2023

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Bios Partners

                            Deal Size : $15.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 ...

                            Details : Proceeds from the financing will primarily support the advancement of ONL1204 Ophthalmic Solution, a novel, first-in-class small molecule Fas inhibitor, into a Phase 2 clinical trial in patients with macula-off rhegmatogenous retinal detachment (RRD).

                            Brand Name : ONL1204

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 08, 2023

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Bios Partners

                            Deal Size : $15.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research

                            Details : ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.

                            Brand Name : ONL1204

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 13, 2023

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic So...

                            Details : ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.

                            Brand Name : ONL1204

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 01, 2023

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society ...

                            Details : ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.

                            Brand Name : ONL1204

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 26, 2023

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AmbioPharm

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AmbioPharm

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : ONL Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Stu...

                            Details : ONL1204 Ophthalmic Solution is a novel, first-in-class small peptide Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions.

                            Brand Name : ONL1204

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 12, 2022

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : ONL Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ONL Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Bios Partners

                            Deal Size : $46.9 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indi...

                            Details : This funding supports the completion of a Phase 1 study in retinal detachment with ONL’s lead compound ONL1204. In addition, the funding will advance ONL1204 in two chronic indications, glaucoma and dry age-related macular degeneration.

                            Brand Name : ONL1204

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 22, 2020

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Bios Partners

                            Deal Size : $46.9 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth